$3.43
-0.59 (-14.68%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
—
1Y
-81.95%
YTD
-81.95%
Open$4.11
Previous Close$4.02
Day High$4.47
Day Low$3.25
52W High$24.09
52W Low$2.15
Volume—
Avg Volume1.20M
Market Cap2.49B
P/E Ratio—
EPS$-1.04
SectorN/A
Technical Indicators
Full analysis →
RSI (14)
72.7
Overbought
Analyst Ratings
Strong Buy
8 analysts
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 897.79M | 924.30M | 800.01M |
| Net Income | 130.26M | 123.87M | 128.43M |
| Profit Margin | 14.5% | 13.4% | 16.1% |
| EBITDA | 262.26M | 279.12M | 215.46M |
| Free Cash Flow | 117.43M | 106.34M | 120.15M |
| Rev Growth | +21.7% | -6.1% | -8.9% |
| Debt/Equity | 0.23 | 0.23 | 0.24 |
N/A Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| PICS | Pics Nv | $9.28 | -2.62% | 4.7 | 1.23B |
| DMII | Drugs Made In America Acquis | $10.19 | +0.15% | 49.8 | 647.83M |
| CCCX | Churchill Capital Corp X-A | $10.08 | -5.62% | — | 2.32B |
| BEAG | Bold Eagle Acquisition Cor-A | $10.87 | +0.18% | 42.8 | 339.80M |
| CEPF | Cantor Equity Partners-Cl A | $10.34 | -0.29% | 41.7 | 592.65M |
| BCSS | Bain Capital Gss Inv- A | $10.29 | -0.10% | 49.0 | 601.52M |